Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proteostasis Therapeutics Inc.

www.proteostasis.com

Latest From Proteostasis Therapeutics Inc.

Vertex' Dueling Phase III Programs Pay Off In NDA Submission Speed

Next-generation CFTR corrector elexacaftor aims to be first cystic fibrosis product with minimal function mutations claim after winning out over VX-659 thanks to tolerability advantage in dueling Phase III programs testing combination with the components of Vertex’ Symdeko.

Respiratory Clinical Trials

Vertex Selects VX-445 For CF Triple Therapy Due To Safety/Tolerability

Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also hopes the benefits of the triple will smooth EU reimbursement talks.

Respiratory Clinical Trials

Proteostasis Puts Best Face On Unspectacular CF Combo Data

With data showing a lung function and sweat chloride benefit for its proprietary CFTR-modulating triplet, Proteostasis says it’s moving ahead. But analysts and investors are concerned the effects are less than seen with Vertex drugs.

Clinical Trials Respiratory

Vertex Stuck Between A Good Place And A Better Place

Two three-drug regimens for cystic fibrosis hit their primary endpoints in both heterozygous and homozygous patients, with good safety and tolerability, which analysts say increases the likelihood one of them will obtain approval.

Business Strategies Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Proteostasis Therapeutics Inc.
  • Senior Management
  • Meenu Chhabra, Pres. & CEO
    Geoffrey Gilmartin, CMO
    Ben Munoz, PhD, CSO
    Marija Zecevic, PhD, COO
  • Contact Info
  • Proteostasis Therapeutics Inc.
    Phone: (617) 225-0096
    80 Guest St., 5th Fl.
    Boston, MA 02135
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register